DAFNA Capital Management LLC - PROQR THRAPEUTICS N V ownership

PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 69 filers reported holding PROQR THRAPEUTICS N V in Q3 2021. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.

Quarter-by-quarter ownership
DAFNA Capital Management LLC ownership history of PROQR THRAPEUTICS N V
ValueSharesWeighting
Q3 2023$1,222,757
-19.8%
940,5820.0%0.38%
-8.9%
Q2 2023$1,523,743
-23.9%
940,5820.0%0.42%
-30.6%
Q1 2023$2,003,440
+314.8%
940,582
+44.8%
0.60%
+362.3%
Q3 2022$483,000
-29.5%
649,383
+659.7%
0.13%
-24.4%
Q4 2021$685,000
-72.4%
85,476
-71.2%
0.17%
-73.9%
Q3 2021$2,481,000
-64.3%
296,383
-71.3%
0.66%
-54.8%
Q2 2021$6,955,000
-4.3%
1,031,880
-6.2%
1.46%
-15.7%
Q1 2021$7,271,000
+39.9%
1,100,000
-11.1%
1.72%
+11.6%
Q4 2020$5,197,000
-12.3%
1,237,4000.0%1.55%
-19.8%
Q3 2020$5,927,000
-21.2%
1,237,4000.0%1.93%
-11.2%
Q2 2020$7,523,000
+10.7%
1,237,4000.0%2.17%
-23.4%
Q1 2020$6,793,000
-38.5%
1,237,400
+11.1%
2.84%
-25.2%
Q4 2019$11,040,000
+633.1%
1,114,000
+326.0%
3.79%
+569.4%
Q3 2019$1,506,000
-36.7%
261,5210.0%0.57%
-36.8%
Q2 2019$2,380,000
-34.4%
261,5210.0%0.90%
-42.8%
Q1 2019$3,627,000
-15.7%
261,521
-4.0%
1.56%
-26.8%
Q4 2018$4,300,000
-14.6%
272,474
+4.7%
2.14%
+3.3%
Q3 2018$5,038,000
+302.7%
260,336
+51.9%
2.07%
+253.1%
Q2 2018$1,251,000
+76.2%
171,351
-25.7%
0.59%
+69.9%
Q1 2018$710,000
-4.6%
230,7700.0%0.34%
-14.0%
Q4 2017$744,000230,7700.40%
Other shareholders
PROQR THRAPEUTICS N V shareholders Q3 2021
NameSharesValueWeighting ↓
Opus Point Partners Management, LLC 307,692$992,0000.86%
DAFNA Capital Management LLC 230,770$744,0000.40%
Redmile Group, LLC 1,558,392$5,026,0000.22%
SPHERA FUNDS MANAGEMENT LTD. 530,000$1,709,0000.20%
SABBY MANAGEMENT, LLC 347,245$1,120,0000.10%
Artal Group S.A. 1,900,000$6,128,0000.09%
Genovese Burford & Brothers Wealth & Retirement Plan Management, LLC 7,500$24,0000.06%
Orbimed Advisors 1,302,955$4,202,0000.05%
ALTRINSIC GLOBAL ADVISORS LLC 191,360$617,0000.02%
JENNISON ASSOCIATES LLC 2,635,552$8,500,0000.01%
View complete list of PROQR THRAPEUTICS N V shareholders